StockData
Acadia Pharmaceuticals Inc logo

Acadia Pharmaceuticals Inc (ACAD) stock

ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3028% below fair value
$17.59−0.24 (-1.35%)

Close on Nov 19, 2026Market cap $3.03BP/E 8.0Yield –

Acadia Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Acadia Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $145.63M, down 22.2% year over year. For fiscal 2025 it was $105.15M, down 33.1% from the year before. The highest annual figure on record is $157.20M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$105.15M-33.1%
FY2024Dec 31, 2024$157.20M+844.0%
FY2023Dec 31, 2023$16.65M–
FY2022Dec 31, 2022-$114.04M–
FY2021Dec 31, 2021-$126.78M–
FY2020Dec 31, 2020-$143.75M–
FY2019Dec 31, 2019-$152.26M–
FY2018Dec 31, 2018-$169.57M–
FY2017Dec 31, 2017-$218.57M–
FY2016Dec 31, 2016-$209.91M–
FY2015Dec 31, 2015-$123.94M–
FY2014Dec 31, 2014-$66.61M–
FY2013Dec 31, 2013-$32.39M–
FY2011Dec 31, 2011-$19.90M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$95.69M+50.3%
Q1 FY2026Mar 31, 2026$28.77M+41.6%
Q4 FY2025Dec 31, 2025-$52.74M-232.1%
Q3 FY2025Sep 30, 2025$73.90M+17.0%
Q2 FY2025Jun 30, 2025$63.66M-25.4%
Q1 FY2025Mar 31, 2025$20.32M–
Q4 FY2024Dec 31, 2024$39.93M–
Q3 FY2024Sep 30, 2024$63.18M–
Q4 FY2023Dec 31, 2023$85.39M–
Q4 FY2022Dec 31, 2022-$23.85M–
Q3 FY2022Sep 30, 2022-$727.00K–
Q2 FY2022Jun 30, 2022-$13.13M–
Q1 FY2022Mar 31, 2022-$76.33M–
Q4 FY2021Dec 31, 2021-$23.12M–
Q3 FY2021Sep 30, 2021-$17.06M–
Q2 FY2021Jun 30, 2021-$25.37M–
Q1 FY2021Mar 31, 2021-$61.23M–
Q4 FY2020Dec 31, 2020-$29.49M–
Q3 FY2020Sep 30, 2020-$24.51M–
Q2 FY2020Jun 30, 2020-$39.82M–
Q1 FY2020Mar 31, 2020-$49.94M–
Q4 FY2019Dec 31, 2019-$29.91M–
Q3 FY2019Sep 30, 2019-$18.93M–
Q2 FY2019Jun 30, 2019-$38.42M–
Q1 FY2019Mar 31, 2019-$65.00M–
Q4 FY2018Dec 31, 2018-$39.61M–
Q3 FY2018Sep 30, 2018-$43.30M–
Q2 FY2018Jun 30, 2018-$40.99M–
Q1 FY2018Mar 31, 2018-$45.68M–
Q4 FY2017Dec 31, 2017-$29.90M–
Q3 FY2017Sep 30, 2017-$58.46M–
Q2 FY2017Jun 30, 2017-$59.16M–
Q1 FY2017Mar 31, 2017-$71.05M–
Q4 FY2016Dec 31, 2016-$61.44M–
Q3 FY2016Sep 30, 2016-$49.73M–

More Acadia Pharmaceuticals figures

See a number that looks wrong?